Neoantigen Targeted Therapies, 2019-2030

AMERICAN CANYON, Calif. - Aug. 18, 2020 - PRLog -- The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:

§  A detailed assessment of the current market landscape of developers engaged in the development of neoantigen targeted therapies.

§  Detailed profiles of developers of neoantigen targeted therapies (shortlisted on the basis of the number of pipeline products).

§  A detailed publication analysis of close to 300 peer-reviewed, scientific articles published during the period 2015-2019 (till February), highlighting the research focus within the industry.

§  An in-depth analysis of the various patents that have been filed / granted related to neoantigens.

§  An analysis of the various partnerships pertaining to neoantigen targeting therapies.

§  An analysis of the investments made at various stages of development in companies that are focused on developing neoantigen targeted therapies.

§  A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

• Target Disease Indication

§  Bone and Cartilage Cancer

§  Colorectal Cancer

§  Head and Neck Cancer

§  Renal Carcinoma

§  Hepatocellular Carcinoma

§  Lung Cancer

§  Gynecological Cancer

§  Others

• Type of Treatment

§  Personalized

§  Off-the-shelf

• Type of Immunotherapy

§  Dendritic Cell Vaccine

§  DNA / RNA-based Vaccine

§  Protein / Peptide-based Vaccine

§  TIL-based Therapy

• Route of Administration

§  Intradermal

§  Intravenous

§  Subcutaneous

§  Others

• Key Geographical Region

§  North America (US)

§  Europe (UK, Germany, France, Italy, and Spain

§  Rest of the World

§  Transcripts of interviews held with the following senior level representatives of stakeholder companies:

Press Release: Variation 1 (Format 2)

• Gabriel Nistor, Chief Scientific Officer, AIVITA Biomedical
• Ella Sorani, Vice President Research and Development, BioLineRx
• Heinz Lubenau, Chief Operating Officer and Co-Founder, VAXIMM

Key companies covered in the report (https://www.rootsanalysis.com/reports/view_document/neoan...)

§  Bavarian Nordic

§  Genocea Biosciences

§  Gradalis

§  Immunicum

§  Immunovative Therapies

§  Iovance Biotherapeutics

§  Medigene

§  Neon Therapeutics

§  Precision Biologics

§  Vaxon Biotech

For more information please click on the following link:

https://www.rootsanalysis.com/reports/view_document/neoantigen-targeted-therapies-market-2019-2030/257.html

Other Recent Offerings

1.      T-Cell Immunotherapies Market (4th Edition), 2019-2030 (https://www.rootsanalysis.com/reports/view_document/t-cel...)

2.      Novel Immuno-Oncology Biomarker Testing Market, 2019-2030

3.      Companion Diagnostics Market (2nd Edition), 2019-2030

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

Gaurav.Chaudhary@rootsanalysis.com